Should a male partner be treated when his female partner has chronic bacterial vaginosis?

Male Partner Treatment for Bacterial Vaginosis

No, male partners should not routinely be treated when their female partner has bacterial vaginosis, based on longstanding CDC guidelines, though groundbreaking 2025 evidence now challenges this recommendation and suggests combined oral and topical antimicrobial therapy for male partners significantly reduces BV recurrence.

Current Guideline Recommendations

The CDC guidelines explicitly state that routine treatment of male sex partners is not recommended for bacterial vaginosis 1, 2, 1. This recommendation is based on the following rationale:

• Treatment of male partners in clinical trials has not influenced the woman's response to therapy, nor has it influenced the relapse or recurrence rate 1
• Male sex partners of women with BV are typically not symptomatic 1
• Preventing transmission to men is not considered a goal of therapy 1

Critical New Evidence That Changes the Landscape

The 2025 StepUp Trial - A Paradigm Shift

A landmark 2025 randomized controlled trial from Australia fundamentally challenges the longstanding guideline recommendations 3. This trial was stopped early by the data and safety monitoring board because treatment of the woman only was clearly inferior to treating both partners:

• BV recurrence occurred in only 35% of women whose male partners received treatment, compared to 63% in the control group (absolute risk difference of -2.6 recurrences per person-year; P<0.001) 3
• The intervention used combined oral metronidazole 400 mg twice daily PLUS 2% clindamycin cream applied to penile skin twice daily for 7 days 3
• This represents a 44% relative reduction in recurrence risk within 12 weeks 3

Why Previous Trials Failed

A 2012 systematic review identified critical flaws in all six prior randomized trials that formed the basis for current guidelines 4:

• Randomization methods were either overtly deficient or insufficiently reported 4
• Five of six trials used suboptimal treatment regimens in women 4
• Adherence to treatment was not reported in women in any trial, and only reported in men in 2 trials 4
• All six trials had limited statistical power 4
• None assessed whether antibiotic treatment affected the penile microbiota 4

Supporting Microbiological Evidence

The 2021 pilot study using 16S rRNA gene sequencing demonstrated the biological plausibility of partner treatment 5:

• Concurrent partner treatment significantly reduced BV-associated bacteria at all three anatomical sites (vagina, penile skin, and male urethra) immediately post-treatment (P = 0.001) 5
• Suppression of BV-associated bacteria was sustained in 81% of women over 12 weeks 5
• Only 17% of women experienced recurrence within 12 weeks, substantially lower than the expected 50% recurrence rate 5

A 2021 RCT found that women whose male partners adhered to study medication were less likely to fail treatment (adjusted relative risk 0.85; 95% CI 0.73-0.99; P = 0.035), though the overall trial was negative 6. This suggests adherence is critical to success.

Clinical Implications and Practical Approach

For Chronic/Recurrent BV

Given the new evidence, consider treating male partners in women with recurrent BV (defined as multiple episodes within 12 months) using the StepUp protocol 3, 7:

Partner Treatment Regimen:

• Metronidazole 400 mg orally twice daily for 7 days 3
• PLUS 2% clindamycin cream applied to penile skin twice daily for 7 days 3
• Couples should abstain from unprotected intercourse during treatment and for 7 days after completion 3

Expected adverse effects in men include:

• Nausea, headache, and metallic taste 3
• These are generally mild and tolerable 5

Important Caveats

This approach is not yet incorporated into U.S. guidelines and represents emerging evidence 7. Key limitations include:

• The StepUp trial was conducted in Australia with a specific population - generalizability to broader U.S. populations requires further study 7
• The trial was open-label (not blinded), which could introduce bias 3
• Long-term outcomes beyond 12 weeks are unknown 3
• Cost-effectiveness and implementation challenges have not been evaluated 7

Patient Counseling Framework

When discussing BV with patients, address the sexual transmission question directly 7, 8:

• BV is associated with sexual activity - women who have never been sexually active are rarely affected, and acquisition is associated with multiple sex partners 1
• However, BV is not considered exclusively a sexually transmitted disease 1
• New evidence suggests sexual exchange of BV-associated organisms between partners contributes to recurrence 3, 8
• For women with recurrent BV in monogamous relationships, partner treatment may reduce recurrence risk 3, 7

When NOT to Treat Partners

Do not routinely treat male partners for first-episode BV - the woman should receive standard first-line therapy alone 1, 2, 1:

Recommended regimens for women:

• Metronidazole 500 mg orally twice daily for 7 days 1, 2
• OR Metronidazole gel 0.75% intravaginally once daily for 5 days 2
• OR Clindamycin cream 2% intravaginally at bedtime for 7 days 2

The Bottom Line

While current CDC guidelines do not recommend routine male partner treatment, the 2025 StepUp trial provides compelling evidence that combined oral and topical antimicrobial therapy for male partners significantly reduces BV recurrence in women with chronic/recurrent disease 3. Until guidelines are updated, clinicians should discuss this new evidence with women experiencing recurrent BV and consider partner treatment on a case-by-case basis, particularly in monogamous relationships where recurrence is problematic 7, 8.